Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Next Previous
X
Search
Trial Profile

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tebentafusp (Primary) ; Dacarbazine; Ipilimumab; Pembrolizumab
  • Indications Uveal melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ATOM
  • Sponsors Immunocore

    • Most Recent Events

    • 04 Jun 2024 Results(n=202)discussing relationship between change in ctDNA at 9 weeks (wks) and overall survival (OS), presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2024 According to an Immunocore media release, clinical data for the treatment of patients with unresectable or metastatic uveal melanoma from this trial were presented at the 2024 ASCO (American Society for Clinical Oncology) Annual Meeting.
    • 05 Jan 2024 According to the Immunocore media release, in 2023, the Company signed an agreement for a European Organisation for Research and Treatment of Cancer (EORTC)-sponsored trial to study KIMMTRAK as adjuvant therapy for uveal (or ocular) melanoma (ATOM). The Company anticipates that the EORTC will randomize the first patient in the second half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top